Reports - Cancer Profiling Market
HealthcareCancer Profiling Market
Cancer Profiling Market: Solutions, Growth & Trends | 2025-2035 by Technology (Immunoassays, Next-Generation Sequencing, Polymerase Chain Reaction, Mass Spectrometry, In-Situ Hybridization, Microarrays, Other Technologies) by Cancer Type (Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Melanoma Cancer, Other Cancer) by Biomarker Type (Genomic Biomarker, Protein Biomarker, Other Biomarker) by Application (Research Application, Clinical Application) by Region (North America, Europe, Asia Pacific, Latin America, Middle East & Africa
Industry Leaders Trust Us For Actionable Intelligence
Table of Contents
Chapter 1 Executive Dashboard
1. Strategic Imperatives
Chapter 2 Premium Insights
1. Top 3 Trends to Watch
2. Demand and Supply Trends
3. Top 3 Strategies Followed by Major Players
4. Top 3 Predictions by Vantage Market Research
5. Top Investment Pockets
6. Insights from Primary Respondents
Chapter 3 Global Cancer Profiling Market - Segment Analysis
1. Overview
2. Global Cancer Profiling Market, 2021 - 2035 (USD Million)
3. Global Cancer Profiling Market - by Technology
3.1. By Immunoassays
3.2. By Next-Generation Sequencing
3.3. By Polymerase Chain Reaction
3.4. By Mass Spectrometry
3.5. By In-Situ Hybridization
3.6. By Microarrays
3.7. By Other Technologies
4. Global Cancer Profiling Market - by Cancer Type
4.1. By Breast Cancer
4.2. By Lung Cancer
4.3. By Colorectal Cancer
4.4. By Prostate Cancer
4.5. By Melanoma Cancer
4.6. By Other Cancer
5. Global Cancer Profiling Market - by Biomarker Type
5.1. By Genomic Biomarker
5.2. By Protein Biomarker
5.3. By Other Biomarker
6. Global Cancer Profiling Market - by Application
6.1. By Research Application
6.2. By Clinical Application
7. Global Cancer Profiling Market - by region
7.1. North America
7.2. Europe
7.3. Asia Pacific
7.4. Latin America
7.5. Middle East & Africa
8. Market comparative analysis
Chapter 4 North America Cancer Profiling Market - Segment Analysis
1. Overview
2. North America Cancer Profiling Market, 2021 - 2035 (USD Million)
3. North America Cancer Profiling Market - by Technology
3.1. By Immunoassays
3.2. By Next-Generation Sequencing
3.3. By Polymerase Chain Reaction
3.4. By Mass Spectrometry
3.5. By In-Situ Hybridization
3.6. By Microarrays
3.7. By Other Technologies
4. North America Cancer Profiling Market - by Cancer Type
4.1. By Breast Cancer
4.2. By Lung Cancer
4.3. By Colorectal Cancer
4.4. By Prostate Cancer
4.5. By Melanoma Cancer
4.6. By Other Cancer
5. North America Cancer Profiling Market - by Biomarker Type
5.1. By Genomic Biomarker
5.2. By Protein Biomarker
5.3. By Other Biomarker
6. North America Cancer Profiling Market - by Application
6.1. By Research Application
6.2. By Clinical Application
Chapter 5 Europe Cancer Profiling Market - Segment Analysis
1. Overview
2. Europe Cancer Profiling Market, 2021 - 2035 (USD Million)
3. Europe Cancer Profiling Market - by Technology
3.1. By Immunoassays
3.2. By Next-Generation Sequencing
3.3. By Polymerase Chain Reaction
3.4. By Mass Spectrometry
3.5. By In-Situ Hybridization
3.6. By Microarrays
3.7. By Other Technologies
4. Europe Cancer Profiling Market - by Cancer Type
4.1. By Breast Cancer
4.2. By Lung Cancer
4.3. By Colorectal Cancer
4.4. By Prostate Cancer
4.5. By Melanoma Cancer
4.6. By Other Cancer
5. Europe Cancer Profiling Market - by Biomarker Type
5.1. By Genomic Biomarker
5.2. By Protein Biomarker
5.3. By Other Biomarker
6. Europe Cancer Profiling Market - by Application
6.1. By Research Application
6.2. By Clinical Application
Chapter 6 Asia Pacific Cancer Profiling Market - Segment Analysis
1. Overview
2. Asia Pacific Cancer Profiling Market, 2021 - 2035 (USD Million)
3. Asia Pacific Cancer Profiling Market - by Technology
3.1. By Immunoassays
3.2. By Next-Generation Sequencing
3.3. By Polymerase Chain Reaction
3.4. By Mass Spectrometry
3.5. By In-Situ Hybridization
3.6. By Microarrays
3.7. By Other Technologies
4. Asia Pacific Cancer Profiling Market - by Cancer Type
4.1. By Breast Cancer
4.2. By Lung Cancer
4.3. By Colorectal Cancer
4.4. By Prostate Cancer
4.5. By Melanoma Cancer
4.6. By Other Cancer
5. Asia Pacific Cancer Profiling Market - by Biomarker Type
5.1. By Genomic Biomarker
5.2. By Protein Biomarker
5.3. By Other Biomarker
6. Asia Pacific Cancer Profiling Market - by Application
6.1. By Research Application
6.2. By Clinical Application
Chapter 7 Latin America Cancer Profiling Market - Segment Analysis
1. Overview
2. Latin America Cancer Profiling Market, 2021 - 2035 (USD Million)
3. Latin America Cancer Profiling Market - by Technology
3.1. By Immunoassays
3.2. By Next-Generation Sequencing
3.3. By Polymerase Chain Reaction
3.4. By Mass Spectrometry
3.5. By In-Situ Hybridization
3.6. By Microarrays
3.7. By Other Technologies
4. Latin America Cancer Profiling Market - by Cancer Type
4.1. By Breast Cancer
4.2. By Lung Cancer
4.3. By Colorectal Cancer
4.4. By Prostate Cancer
4.5. By Melanoma Cancer
4.6. By Other Cancer
5. Latin America Cancer Profiling Market - by Biomarker Type
5.1. By Genomic Biomarker
5.2. By Protein Biomarker
5.3. By Other Biomarker
6. Latin America Cancer Profiling Market - by Application
6.1. By Research Application
6.2. By Clinical Application
Chapter 8 Middle East & Africa Cancer Profiling Market - Segment Analysis
1. Overview
2. Middle East & Africa Cancer Profiling Market, 2021 - 2035 (USD Million)
3. Middle East & Africa Cancer Profiling Market - by Technology
3.1. By Immunoassays
3.2. By Next-Generation Sequencing
3.3. By Polymerase Chain Reaction
3.4. By Mass Spectrometry
3.5. By In-Situ Hybridization
3.6. By Microarrays
3.7. By Other Technologies
4. Middle East & Africa Cancer Profiling Market - by Cancer Type
4.1. By Breast Cancer
4.2. By Lung Cancer
4.3. By Colorectal Cancer
4.4. By Prostate Cancer
4.5. By Melanoma Cancer
4.6. By Other Cancer
5. Middle East & Africa Cancer Profiling Market - by Biomarker Type
5.1. By Genomic Biomarker
5.2. By Protein Biomarker
5.3. By Other Biomarker
6. Middle East & Africa Cancer Profiling Market - by Application
6.1. By Research Application
6.2. By Clinical Application
Chapter 9 Key Market Dynamics
1. Introduction
2. Market Drivers
3. Market Restraints
4. Market Opportunities
5. Porter's Five Forces Analysis
6. PEST Analysis
7. Regulatory Landscape
8. Technology Landscape
9. Regional Market Trends
Chapter 10 COVID 19 Impact Analysis
1. Key strategies undertaken by companies to tackle COVID-19
2. Short term dynamics
3. Long term dynamics
Chapter 11 Marketing Strategy Analysis
1. Marketing Channel
2. Direct Marketing
3. Indirect Marketing
4. Marketing Channel Development Trends
Chapter 12 Competitive Landscape
1. Competition Matrix - 2021
2. Company Market Share Analysis - 2021
3. Key Company Activities, 2018 - 2021
4. Strategic Developments - Heat Map Analysis
5. Company Offering Evaluation
6. Company Regional Presence Evaluation
Chapter 13 Company Profiles
1. Illumina Inc. (U.S.)
2. QIAGEN (Germany)
3. NeoGenomics Laboratories Inc. (U.S.)
4. HTG Molecular Diagnostics Inc. (U.S.)
5. Genomic Health Inc. (U.S.)
6. Caris Life Sciences (U.S.)
7. Helomics Corporation (U.S.)
8. NanoString Technologies Inc. (U.S.)
9. Sysmex Corporation (Japan)
10. Ribomed Biotechnologies Inc. (U.S.)
11. Guardant Health Inc. (U.S.)
12. Foundation Medicine (U.S.) Roche Diagnostics (Switzerland)
13. (U.S.)
14. GenScript Biotech Corporation (China)
15. Tempus Labs (U.S.)
16. Boreal Genomics Inc (Canada)
17. Perthera (U.S.)
18. Agendia (U.S.)
19. Omniseq (U.S.) Histogene X (Belgium)
Chapter 14 Key Primary Respondents - VERBATIM
Chapter 15 Discussion Guide
Chapter 16 Customization Offered
Chapter 17 Annexure
Chapter 18 List of Figures
Chapter 19 List of Tables
Chapter 20 List of Abbreviations
FAQ‘s
Related Reports
Contact
Toll Free Number+1 (877) 462-2282
© 2025 Vantage Market Research. All right reserved
Secured By